Cover Image
市場調查報告書

肢端肥大症及巨人症:機會分析·預測 2018年

OpportunityAnalyzer: Acromegaly and Gigantism - Opportunity Analysis and Forecast to 2018

出版商 GlobalData 商品編碼 325934
出版日期 內容資訊 英文 160 Pages
訂單完成後即時交付
價格
Back to Top
肢端肥大症及巨人症:機會分析·預測 2018年 OpportunityAnalyzer: Acromegaly and Gigantism - Opportunity Analysis and Forecast to 2018
出版日期: 2014年12月31日 內容資訊: 英文 160 Pages
簡介

2013年全球肢端肥大症·巨人症市場銷售額約為5億8,800萬美金。該市場預計在五年間將以3.7%的年複合成長率穩定成長,到2018年末將創造7億700萬美金的銷售額。美國市場預測將以4.58%的年複合成長率成長,到2018年約創造全球銷售額的68%,成長率將為EU5國的二倍。

本報告提供全球肢端肥大症·巨人症市場相關調查,提供疾病概要,目前治療選項,機會分析,R&D策略及開發平台評估等彙整資料,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因與病理學
    • 病因
    • 病理學
  • 症狀
  • 預後
  • 生活品質 (QOL)

第4章 流行病學

  • 疾病的背景
  • 風險因素·併發症
  • 全球趨勢
  • 預測手法
  • 肢端肥大症的流行病學預測
  • 巨人症的流行病學的預測
  • 伴隨大腺瘤,微腺瘤,及外科治療的肢端肥大症·巨人症之流行病學預測
  • 議論

第5章 目前治療選項

  • 疾病診斷
  • 治療目標的標準
  • 治療概要
  • 臨床診療
  • 產品簡介:生長抑制素類似體
  • 產品簡介:生長激素受體拮抗劑
  • 產品簡介:多巴胺促效劑

第6章 未滿足需求的評估·機會分析

  • 概要
  • 提高功效·安全性
  • 治療併發症
  • 醫生·患者教育
  • 改善化驗標準化

第7章 R&D策略

  • 概要
  • 臨床實驗設計

第8章 開發平台評估

  • 概要
  • 臨床開發的潛力藥劑
  • 其他階段III實驗
  • 初期階段的創新方法

第9章 開發平台評估分析

  • 主要的開發平台藥物臨床基準
  • 主要的開發平台藥物的商業基準
  • 競爭評估
  • 銷售額的5年預測

第10章 附錄

圖表清單

目錄
Product Code: GDHC028POA

GlobalData estimates the 2013 sales for acromegaly and gigantism at approximately $588m across the 6MM covered in this report. The market will grow moderately at a CAGR of 3.74% during the five year forecast period, generating sales of approximately $707m at the end of 2018. Growing at a CAGR of 4.58% and generating around 68% of global sales in 2018, the US market will experience twice the rate of growth of the 5EU market. Two major trends are visible among the pipeline drugs and research and development (R&D) strategies employed by companies in this chronic disease space - a focus towards the treatment of refractory patients and the improvement of drug delivery mechanisms to increase patient convenience.

Highlights

Key Questions Answered

  • Although the standard treatments are effective in most patients, a growing number of patients are being discovered who remain uncontrolled by current therapy. Treatment of this patient segment presents a major unmet need in this market. There are other prominent unmet needs highlighted by the Key Opinion Leaders (KOLs). What are these? Will the pipeline drugs fulfil these unmet needs of the market?
  • The five-year forecast period will mark the patent expirations of the major branded drugs in this market and the launch of three pipeline agents. How will the sales of the existing drugs be impacted? Which of the pipeline drugs will have the highest peak sales at the highest CAGR, and why?
  • What are the major R&D strategies employed by companies in this disease space? What do KOLs think of these strategies? What are other opportunities for new entrants seeking to enter this market?

Key Findings

  • One of the main drivers of the acromegaly and gigantism market during the forecast period will be the increased use of somatostatin analogs with better administration or dosing regimens; due to the recent focus on improving patient convenience for this chronic disease area.
  • Another strong driver will be the treatment of refractory patient segments, which will lead to an overall increase in the drug treatment rate.
  • Greater disease awareness and management of comorbidities are two of the biggest unmet needs in this market.
  • Variation in clinical trial methodologies have hindered direct comparison of drug efficacy rates. Trial design needs to be improved by incorporating more randomized, head-to-head, prospective studies.
  • The dominant trend among the pipeline drugs is towards development of novel drug delivery methods, rather than the exploration of new mechanisms of action.

Scope

  • Overview of acromegaly and gigantism, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized acromegaly and gigantism therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for five years to 2018.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the acromegaly and gigantism therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global acromegaly and gigantism therapeutics market. Insightful review of the key industry drivers, restraints and challenges.
  • Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the acromegaly and gigantism therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the acromegaly and gigantism therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the 6MM acromegaly and gigantism therapeutics market from 2013-2018.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis
  • 3.4. Quality of Life

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods
  • 4.5. Epidemiological Forecast for Acromegaly (2013-2023)
    • 4.5.1. Diagnosed Prevalent Cases of Acromegaly
    • 4.5.2. Age-Specific Diagnosed Prevalent Cases of Acromegaly
    • 4.5.3. Sex-Specific Diagnosed Prevalent Cases of Acromegaly
    • 4.5.4. Age-Standardized Diagnosed Prevalence of Acromegaly
  • 4.6. Epidemiological Forecast for Gigantism (2013-2023)
    • 4.6.1. Diagnosed Prevalent Cases of Gigantism
    • 4.6.2. Age-Specific Diagnosed Prevalent Cases of Gigantism
    • 4.6.3. Sex-Specific Diagnosed Prevalent Cases of Gigantism
    • 4.6.4. Age-Standardized Diagnosed Prevalence of Gigantism
  • 4.7. Epidemiological Forecast for Acromegaly and Gigantism with Macroadenomas, Microadenomas, and Cases Receiving Any Surgical Treatment (2013-2023)
    • 4.7.1. Diagnosed Prevalent Cases of Acromegaly and Gigantism with Macroadenomas
    • 4.7.2. Diagnosed Prevalent Cases of Acromegaly and Gigantism with Microadenomas
    • 4.7.3. Diagnosed Prevalent Cases of Acromegaly and Gigantism Receiving Any Surgical Treatment
  • 4.8. Discussion
    • 4.8.1. Epidemiological Forecast Insight
    • 4.8.2. Limitations of the Analysis
    • 4.8.3. Strengths of the Analysis

5. Current Treatment Options

  • 5.1. Disease Diagnosis
  • 5.2. Criteria for Cure and Treatment Goals
  • 5.3. Treatment Overview
  • 5.4. Clinical Practice
  • 5.5. Product Profiles - Somatostatin Analogs
    • 5.5.1. Sandostatin SC and Sandostatin LAR Depot (Octreotide Acetate)
    • 5.5.2. Somatuline LA and Somatuline Depot (Lanreotide Acetate)
  • 5.6. Product Profile - Growth Hormone Receptor Antagonists
    • 5.6.1. Somavert (Pegvisomant)
  • 5.7. Product Profiles - Dopamine Agonists
    • 5.7.1. Cabergoline and Bromocriptine (Widely Genericized)

6. Unmet Needs Assessment and Opportunity Analysis

  • 6.1. Overview
  • 6.2. Improved Efficacy and Safety
    • 6.2.1. Unmet Needs
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Treatment of Comorbidities
    • 6.3.1. Unmet Needs
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Physician and Patient Education
    • 6.4.1. Unmet Needs
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity Analysis
  • 6.5. Improvement in Assay Standardization
    • 6.5.1. Unmet Needs
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity Analysis

7. R&D Strategies

  • 7.1. Overview
    • 7.1.1. Targeting Refractory Patients by Improving Existing Drug Classes
    • 7.1.2. Novel Drug Delivery Strategies
    • 7.1.3. Reformulation Strategies to Reduce Dosing Frequency
    • 7.1.4. Licensing and Acquisitions
  • 7.2. Clinical Trial Design
    • 7.2.1. Current Clinical Trial Design
    • 7.2.2. Future Clinical Trial Design

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Promising Drugs in Clinical Development
    • 8.2.1. Signifor LAR (Pasireotide)
    • 8.2.2. Oral Octreotide (Octreotide Acetate)
    • 8.2.3. ATL1103
  • 8.3. Other Phase III Trials
  • 8.4. Innovative Early-Stage Approaches

9. Pipeline Valuation Analysis

  • 9.1. Clinical Benchmark of Key Pipeline Drugs
  • 9.2. Commercial Benchmark of Key Pipeline Drugs
  • 9.3. Competitive Assessment
  • 9.4. Top-Line Five-Year Forecast
    • 9.4.1. US
    • 9.4.2. 5EU

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Methodology
  • 10.4. Forecasting Methodology
    • 10.4.1. Diagnosed Acromegaly and Gigantism Patients
    • 10.4.2. Percent of Drug-Treated Patients
    • 10.4.3. Drugs Included in Each Therapeutic Class
    • 10.4.4. Launch and Patent Expiry Dates
    • 10.4.5. General Pricing Assumptions
    • 10.4.6. Individual Drug Assumptions
    • 10.4.7. Generic Erosion
    • 10.4.8. Pricing of Pipeline Agents
  • 10.5. Physicians and Specialists Included in this Study
  • 10.6. About the Authors
    • 10.6.1. Analyst
    • 10.6.2. Epidemiologist
    • 10.6.3. Therapy Director - CVMD
    • 10.6.4. Global Head of Healthcare
  • 10.7. About GlobalData
  • 10.8. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for Acromegaly and Gigantism
  • Table 2: Summary of the Global Reported Cases and Estimated Prevalence of Acromegaly
  • Table 3: Global Consensus Criteria for the Diagnosis and Cure of Acromegaly
  • Table 4: Sources of Acromegaly and Gigantism Prevalence Data in the 6MM
  • Table 5: Sources of Macroadenoma, Microadenoma, and Surgery Data in the 6MM
  • Table 6: 6MM, Diagnosed Prevalent Cases of Acromegaly, Both Sexes, Ages ≥15 Years, N, 2013-2023
  • Table 7: 6MM, Age-Specific Diagnosed Prevalent Cases of Acromegaly, Both Sexes, N (Row %), 2013
  • Table 8: 6MM, Sex-Specific Diagnosed Prevalent Cases of Acromegaly, Ages ≥15 Years, N (Row %), 2013
  • Table 9: 6MM, Diagnosed Prevalent Cases of Gigantism, Both Sexes, All Ages, N, 2013-2023
  • Table 10: 6MM, Age-Specific Diagnosed Prevalent Cases of Gigantism, Both Sexes, N (Row %), 2013
  • Table 11: 6MM, Sex-Specific Diagnosed Prevalent Cases of Gigantism, All Ages, N (Row %), 2013
  • Table 12: Leading Treatments for Acromegaly
  • Table 13: Comparative Assessment of Leading Pharmacological Drug Treatments for Acromegaly
  • Table 14: Product Profile - Sandostatin SC and Sandostatin LAR Depot
  • Table 15: Sandostatin LAR Depot SWOT Analysis, 2014
  • Table 16: Product Profile - Somatuline LA and Somatuline Depot
  • Table 17: Somatuline Depot SWOT Analysis, 2014
  • Table 18: Product Profile - Somavert
  • Table 19: Somavert SWOT Analysis, 2014
  • Table 20: Unmet Needs in Acromegaly
  • Table 21: Examples of Pivotal Trials for Approved Treatments for Acromegaly
  • Table 22: Acromegaly - Late-Stage Pipeline, 2014
  • Table 23: Product Profile - Signifor LAR
  • Table 24: Signifor LAR SWOT Analysis, 2014
  • Table 25: Product Profile - Oral Octreotide
  • Table 26: Oral Octreotide SWOT Analysis, 2014
  • Table 27: Product Profile - ATL1103
  • Table 28: ATL1103 SWOT Analysis, 2014
  • Table 29: Early-Stage Pipeline Products in Acromegaly
  • Table 30: Clinical Benchmark of Signifor LAR and Oral Octreotide
  • Table 31: Clinical Benchmark of ATL1103
  • Table 32: Commercial Benchmark of Signifor LAR and Oral Octreotide
  • Table 33: Commercial Benchmark of ATL1103
  • Table 34: Top-Line Sales Forecasts ($m) for Acromegaly and Gigantism, 2013-2018
  • Table 35: Key Events Impacting Sales for Acromegaly and Gigantism, 2013-2018
  • Table 36: Acromegaly and Gigantism Market - Drivers and Barriers, 2013-2018
  • Table 37: Key Launch Dates
  • Table 38: Key Patent Expiries

List of Figures

  • Figure 1: Overview of GH/IGF-1 Pathway and Targets of Medical Therapy for Acromegaly and Gigantism
  • Figure 2: 6MM, Diagnosed Prevalent Cases of Acromegaly, Both Sexes, Ages ≥15 Years, N, 2013-2023
  • Figure 3: 6MM, Age-Specific Diagnosed Prevalent Cases of Acromegaly, Both Sexes, Ages ≥15 Years, N, 2013
  • Figure 4: 6MM, Sex-Specific Diagnosed Prevalent Cases of Acromegaly, Ages ≥15 Years, N, 2013
  • Figure 5: 6MM, Age-Standardized Diagnosed Prevalence of Acromegaly (Cases per Million Population), Ages ≥15 Years, by Sex, 2013
  • Figure 6: 6MM, Diagnosed Prevalent Cases of Gigantism, Both Sexes, All Ages, N, 2013-2023
  • Figure 7: 6MM, Age-Specific Diagnosed Prevalent Cases of Gigantism, Both Sexes, All Ages, N, 2013
  • Figure 8: 6MM, Sex-Specific Diagnosed Prevalent Cases of Gigantism, All Ages, N, 2013
  • Figure 9: 6MM, Age-Standardized Diagnosed Prevalence of Gigantism (Cases per Million Population), All Ages, by Sex, 2013
  • Figure 10: 6MM, Diagnosed Prevalent Cases of Acromegaly (Ages ≥15 Years) and Gigantism (All Ages) with Macroadenomas, Both Sexes, N, 2013 and 2023
  • Figure 11: 6MM, Diagnosed Prevalent Cases of Acromegaly (Ages ≥15 Years) and Gigantism (All Ages) with Microadenomas, Both Sexes, N, 2013 and 2023
  • Figure 12: 6MM, Diagnosed Prevalent Cases of Acromegaly (Ages ≥15 Years) and Gigantism (All Ages) Receiving Any Surgical Treatment, Both Sexes, N, 2013 and 2023
  • Figure 13: Acromegaly Treatment Management
  • Figure 14: Pharmacological Therapy Management in Acromegaly
  • Figure 15: Competitive Assessment of Signifor LAR and Oral Octreotide, 2013-2018
  • Figure 16: Competitive Assessment of ATL1103, 2013-2018
  • Figure 17: Sales for the Acromegaly and Gigantism Market in the US and 5EU, 2013-2018
Back to Top